Correlation Between Bluejay Diagnostics and Pasithea Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Bluejay Diagnostics and Pasithea Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bluejay Diagnostics and Pasithea Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bluejay Diagnostics and Pasithea Therapeutics Corp, you can compare the effects of market volatilities on Bluejay Diagnostics and Pasithea Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bluejay Diagnostics with a short position of Pasithea Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bluejay Diagnostics and Pasithea Therapeutics.

Diversification Opportunities for Bluejay Diagnostics and Pasithea Therapeutics

-0.45
  Correlation Coefficient

Very good diversification

The 3 months correlation between Bluejay and Pasithea is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Bluejay Diagnostics and Pasithea Therapeutics Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pasithea Therapeutics and Bluejay Diagnostics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bluejay Diagnostics are associated (or correlated) with Pasithea Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pasithea Therapeutics has no effect on the direction of Bluejay Diagnostics i.e., Bluejay Diagnostics and Pasithea Therapeutics go up and down completely randomly.

Pair Corralation between Bluejay Diagnostics and Pasithea Therapeutics

Given the investment horizon of 90 days Bluejay Diagnostics is expected to under-perform the Pasithea Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Bluejay Diagnostics is 22.41 times less risky than Pasithea Therapeutics. The stock trades about -0.08 of its potential returns per unit of risk. The Pasithea Therapeutics Corp is currently generating about 0.29 of returns per unit of risk over similar time horizon. If you would invest  1.11  in Pasithea Therapeutics Corp on September 26, 2024 and sell it today you would earn a total of  1.19  from holding Pasithea Therapeutics Corp or generate 107.21% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy47.2%
ValuesDaily Returns

Bluejay Diagnostics  vs.  Pasithea Therapeutics Corp

 Performance 
       Timeline  
Bluejay Diagnostics 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Bluejay Diagnostics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile fundamental indicators, Bluejay Diagnostics showed solid returns over the last few months and may actually be approaching a breakup point.
Pasithea Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Weak
Over the last 90 days Pasithea Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly unsteady basic indicators, Pasithea Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Bluejay Diagnostics and Pasithea Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Bluejay Diagnostics and Pasithea Therapeutics

The main advantage of trading using opposite Bluejay Diagnostics and Pasithea Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bluejay Diagnostics position performs unexpectedly, Pasithea Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pasithea Therapeutics will offset losses from the drop in Pasithea Therapeutics' long position.
The idea behind Bluejay Diagnostics and Pasithea Therapeutics Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Complementary Tools

Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance